US14843C1053
© Globe Newswire
12.12.2025
CSTL
LISTED
NASDAQ
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
News Preview
Castle announced the publication of a new systematic review and meta-analysis related to its TissueCypher test in the Journal of Clinical Gastroenterology....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CSTL
LISTED
NASDAQ
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
News Preview
Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
News Preview
Castle earns 4 Top Workplaces Awards—Houston Top Workplace plus 3 Culture Excellence Awards—bringing their 2025 total Top Workplaces Awards to 13...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
14.11.2025
CSTL
LISTED
NASDAQ
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
News Preview
Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
11.11.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Reports Third Quarter 2025 Results
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the third quarter and nine months ended Sept. 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.10.2025
CSTL
LISTED
NASDAQ
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
News Preview
Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
CSTL
LISTED
NASDAQ
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
News Preview
Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
News Preview
Castle Biosciences will release Q3 2025 financial results and host conference call on Monday, Nov. 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
CSTL
LISTED
NASDAQ
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
News Preview
Castle Biosciences' Founder, President & CEO Derek Maetzold awarded CEO of the Year by The CEO Magazine...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
News Preview
Castle Biosciences has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
News Preview
Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
09.09.2025
CSTL
LISTED
NASDAQ
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
News Preview
Castle will share new data on its TissueCypher Barrett’s Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting....
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2025
CSTL
LISTED
NASDAQ
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
News Preview
USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2025
CSTL
LISTED
NASDAQ
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
News Preview
USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
CSTL
LISTED
NASDAQ
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
News Preview
Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
News Preview
Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
CSTL
LISTED
NASDAQ
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
News Preview
Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
CSTL
LISTED
NASDAQ
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
News Preview
Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
News Preview
Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
News Preview
Castle Biosciences will release Q2 2025 financial results and host conference call on Monday, Aug. 4, 2025 at 4:30 p.m. ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.06.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 66 employees covering an aggregate of 135,9...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
News Preview
Castle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.06.2025
CSTL
LISTED
NASDAQ
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
News Preview
Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
News Preview
Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Celebrates Skin Cancer Awareness Month
News Preview
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Reports First Quarter 2025 Results
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the first quarter ended March 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Acquire Previse
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL) has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2025
CSTL
LISTED
NASDAQ
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
News Preview
Castle Biosciences will share new data on its TissueCypher test for patients with Barrett’s esophagus at DDW 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
CSTL
LISTED
NASDAQ
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
News Preview
Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
CSTL
LISTED
NASDAQ
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
News Preview
Castle Biosciences will share new data intended to improve the care of patients with cutaneous and uveal melanoma at the AACR Annual Meeting 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.04.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
News Preview
Castle will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.04.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
News Preview
Castle is supporting key educational programs and initiatives throughout April in recognition of Esophageal Cancer Awareness Month....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.04.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
News Preview
Castle announces 4th Top Workplaces USA win, ranking 30th of 358 U.S. companies with 500-999 employees...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
CSTL
LISTED
NASDAQ
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
News Preview
Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.03.2025
CSTL
LISTED
NASDAQ
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
News Preview
Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference....
Themefolio
Profiler
Peergroup
© BusinessWire
07.03.2025
CSTL
LISTED
NASDAQ
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting, taking place March 7-11 in Orlando, Florida.
“At Castle, we are dedicated to empowering clinici...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024.
“Castle delivered an outstanding fourth quarter that rounded out an exceptional 2024, including 51% revenue growth and 36% test report...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Participate in Upcoming Investor Conferences
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month:
Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern tim...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii.
“As long-standing supp...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
CSTL
LISTED
NASDAQ
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025.
Company management will host a conference call and webcast to d...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
CSTL
LISTED
NASDAQ
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin cancer, DecisionDx-SCC, DecisionDx®-Melanoma and MyPath® Melanoma, through poster presentations at the annual Maui Derm Hawaii meeting, being held Jan. 20-24,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024.
“Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the st...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
CSTL
LISTED
NASDAQ
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett’s Esophagus test. TissueCypher is the first AI-driven precision medicine test designed to predic...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company’s ongoing pro...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
CSTL
LISTED
NASDAQ
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new independent meta-analysis in Cancers assessing the efficacy of its DecisionDx-Melanoma test in predicting melanoma patient outcomes. The article, titled “The Prognostic Value of the 31-Gene...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
CSTL
LISTED
NASDAQ
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time.
A live audio webcast of the C...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area’s top workplaces. Castle also earned thr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
CSTL
LISTED
NASDAQ
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago.
“At Castle, w...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s Esophagus test, which surpassed 25,000 test reports delivered since the Company acquired the test at the end of 2021.
“At Castle, improving patient c...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
CSTL
LISTED
NASDAQ
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the latest data from its prospective, multicenter DECIDE study exploring the impact of integrating DecisionDx-Melanoma test results into SLNB decision-making for patients recently diagnosed with melanoma. The update...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Reports Third Quarter 2024 Results
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024.
“We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedi...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating a significant reduction in healthcare management costs and an improvement in the quality of life for patients with Barrett’s esophagus (BE) whose management is guided by its TissueCypher test....
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
CSTL
LISTED
NASDAQ
Castle Biosciences to Participate in Upcoming Investor Conferences
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month:
Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. East...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2024
CSTL
LISTED
NASDAQ
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding risk-aligned treatment decisions, including SLNB for patients with melanoma and surveillance imaging for those...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
CSTL
LISTED
NASDAQ
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma gene expression profile (GEP) test, designed to aid in providing an accurate diagnosis for ambiguous m...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
CSTL
LISTED
NASDAQ
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024.
Company management will host a conference call and webcast t...
Themefolio
Profiler
Peergroup
© BusinessWire
11.10.2024
CSTL
LISTED
NASDAQ
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the Oregon Health & Science University (OHSU) Department of Dermatology and being held Oct. 17-21, 2024, in Stevenson...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
CSTL
LISTED
NASDAQ
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
News Preview
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx®-UM tests for patients with cutaneous melanoma (CM) and uveal melanoma (UM), respectively, at the 21st International Congress of the So...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
